The Zhitong Finance App learned that CMB International released a research report stating that it will raise the target price of Collumbotai Biotech (06990) by 0.5% from HK$642.99 to HK$645.62, maintaining the “buy” rating.

The bank said it will raise the DCF-based target price from HK$642.29 to HK$645.62 considering the smooth progress of SAC-TMT development. Short-term catalysts include ASCENT-GYN readings around the end of 2026, SAC-TMT approval progress in EC, further Trofuse Phase III data in 2027, and the launch of MK-2010 Joint SAC-TMT Phase III research in the first half of 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.